Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 3 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Direct to Consumer (DTC) Advertising in Pharmaceuticals -Introduction | 8 | 3 |
| Direct to Consumer (DTC) Advertising in Pharmaceuticals Media Types | 11 | 28 |
| Traditional Media Types | 13 | 1 |
| Television | 13 | 1 |
| Introduction | 13 | 1 |
| Advertising Regulations and Violative Campaigns | 14 | 2 |
| Expenditure | 16 | 1 |
| Television Advertising within the Media Mix | 16 | 1 |
| Print | 17 | 1 |
| Other | 18 | 1 |
| Online and Social Media | 18 | 1 |
| Introduction | 18 | 1 |
| Impact | 18 | 1 |
| FDA Guidance | 19 | 1 |
| Advertisement Placement | 20 | 1 |
| Twitter | 21 | 1 |
| Introduction | 21 | 3 |
| AstraZeneca s Live Twitter Chat | 24 | 2 |
| Shire s @ADHD Support | 26 | 1 |
| Facebook | 27 | 1 |
| YouTube | 27 | 1 |
| Mobile | 28 | 1 |
| The Importance of a Mobile-enabled Website | 28 | 1 |
| Applications | 28 | 1 |
| Managing Media Types | 29 | 1 |
| Increasing and Measuring ROI of Social Media | 29 | 7 |
| Choosing the Correct Media Mix | 36 | 1 |
| Nature of the Disease | 36 | 1 |
| Prevalence of the Disease | 37 | 1 |
| Consumer Media Preferences and/or Habits | 37 | 1 |
| Target Population | 37 | 1 |
| Degree of Market Competition | 37 | 1 |
| Future Prospects for a Brand | 37 | 1 |
| Future Prospects for the Market | 38 | 1 |
| DTC Advertising in the US | 39 | 12 |
| Introduction | 39 | 1 |
| History of DTC in the US | 39 | 2 |
| Impact of DTC in the US | 41 | 1 |
| Current DTC US Market | 42 | 2 |
| FDA Regulations | 44 | 1 |
| 2011 Guidance for Industry the FDAs Response to Social Media Use | 44 | 1 |
| 45-Day Ad Review | 45 | 1 |
| Innovative Campaign Examples | 46 | 1 |
| Lantus (Insulin Glargine) Sanofi US | 46 | 1 |
| Spiriva Boehringer Ingelheim Pharmaceuticals Inc. | 46 | 1 |
| Controversial Campaign Examples | 47 | 1 |
| Copaxone (Glatiramer Acetate) Teva Pharmaceutical Industries | 47 | 2 |
| Victoza (Liraglutide [rDNA Origin] Injection) Novo Nordisk A/S | 49 | 2 |
| European Union | 51 | 4 |
| Introduction | 51 | 1 |
| EU Regulations for DTC Advertising | 51 | 1 |
| High Level Pharmaceutical Forum A Move to Push Branded DTC Advertising in Europe | 52 | 1 |
| EC Proposal on Restricted Branded Advertising Possible Entry Point for DTC Advertising Penetration in the Continent | 52 | 1 |
| Budget Cuts and National Health Services | 53 | 1 |
| Awareness Campaigns | 53 | 1 |
| Dupuytren s Disease it is in your hands | 53 | 1 |
| Lust for Life | 53 | 1 |
| Conclusion | 54 | 1 |
| Other Markets | 55 | 1 |
| New Zealand | 55 | 1 |
| Trans-Tasman Initiative | 55 | 1 |
| Conclusion | 56 | 1 |
| Key Takeaway | 57 | 1 |
| Appendix | 58 | 5 |
| Market Definitions | 58 | 1 |
| Social Media Definitions | 58 | 1 |
| Abbreviations | 59 | 1 |
| Sources | 59 | 1 |
| Research Methodology | 60 | 3 |
| Coverage | 60 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Competitive Landscape | 61 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 62 | 1 |